COMMUNIQUÉS West-GlobeNewswire

-
BioPorto Presenting FDA-cleared ProNephro AKI (NGAL) at ASN Kidney Week 2024 Conference
23/10/2024 -
Rapafusyn Announces an Upcoming Oral Presentation at Targeted Protein Degradation & Induced Proximity Summit
23/10/2024 -
Le KFSHRC s’impose comme le plus important programme de transplantation rénale par don croisé au monde, avec 500 transplantations réussies
23/10/2024 -
KFSHRC Performs World First Robotic Left Liver Lobe Transplant
23/10/2024 -
Bloo Pharmapeutica Introduces Age-Defying Methylene Blue Bath Solution: Aqua Miraculorum “Water of Miracles”
23/10/2024 -
HiberCell Receives FDA Fast Track Designation for HC-7366 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML)
23/10/2024 -
Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium
23/10/2024 -
Humber River Health Embarks on $100 Million Fundraising Mission to Cure Healthcare
23/10/2024 -
Adial Pharmaceuticals to Present at the 2024 ThinkEquity Conference
23/10/2024 -
Outset Medical to Report Third Quarter 2024 Financial Results on Wednesday, November 6, 2024
23/10/2024 -
Topline Results from Alkeus Pharmaceuticals’ Study of Oral Gildeuretinol Demonstrate Significant Trend in Slowing GA Progression and Visual Function Improvement
23/10/2024 -
Stereotaxis to Report Third Quarter 2024 Financial Results on November 11, 2024
23/10/2024 -
VIVUS Announces Label Update for QSYMIA®
23/10/2024 -
New Analysis of Phase 3 Data Demonstrating Renal Protective Benefits of Sotagliflozin to be Presented at ASN Kidney Week 2024
23/10/2024 -
Visory Health Announces Folds of Honor Partnership to Bring Affordable Medications to Veterans
23/10/2024 -
Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors
23/10/2024 -
Major shareholder announcement
23/10/2024 -
Tevogen Bio’s Effort in Artificial Intelligence, Tevogen AI, Joins Microsoft for Startups, Begins Accelerating drug Development
23/10/2024 -
Calidi Biotherapeutics Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private Placement
23/10/2024
Pages